Samarium-153 therapy for prostate cancer: The evaluation of urine activity, staff exposure and dose rate from patients
| dc.contributor.author | Parlak Y. | |
| dc.contributor.author | Gumuser G. | |
| dc.contributor.author | Sayit E. | |
| dc.date.accessioned | 2025-04-10T11:10:30Z | |
| dc.date.available | 2025-04-10T11:10:30Z | |
| dc.date.issued | 2015 | |
| dc.description.abstract | The aim of this study was to determine the excretion of Samarium-153-ethylenediaminetetramethylphosphonic acid (153Sm- EDTMP) in urine and to calculate the dose rate of its retention in the body as a function of time and the dose received by the skin of laboratory staff 's finger. Urine samples were collected from 11 patients after intravenous injection of 153Sm-EDTMP. The measurements of dose rate were performed. Thermoluminescent dosemeters were used for absorbed dose measurements. Effective half-lives that were calculated from urine sample measurements were found as 7.1±3 h within the first 24 h. Whole body dose rates before collecting urine of patients were 60.0 ± 15.7 μSv h21 for within 1 h following 153Sm-EDTMP administration. The highest finger radiation dose is to the right-hand thumb (3.8 ± 2 mGy). The results of the study imply that patients who recieved 153Sm-EDTMP therapy should be kept a minumum of 8 h in an isolated room at hospital and that one staff should give therapy at most two patients per week. © The Author 2014. | |
| dc.identifier.DOI-ID | 10.1093/rpd/ncu237 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/49229 | |
| dc.publisher | Oxford University Press | |
| dc.title | Samarium-153 therapy for prostate cancer: The evaluation of urine activity, staff exposure and dose rate from patients | |
| dc.type | Article |